Drug · DIN 02486571
HYPERRAB
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 2, 2019; first marketed July 2, 2019.
- Drug Identification Number (DIN)
- 02486571
- Company (DIN owner)
- Grifols Therapeutics LlcClayton, North Carolina, United States
- Schedule
- Schedule d
- Dosage form
- Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Rabies immunoglobulin J06BB05
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RABIES IMMUNOGLOBULIN (HUMAN) | 300 UNIT | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 13, 2019: NOC 21971Supplement to a New Drug Submission (SNDS) · Changes to the manufacturing process